FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3033436222> ?p ?o ?g. }

• W3033436222 endingPage "1542" @default.
• W3033436222 startingPage "1533" @default.
• W3033436222 abstract "Abstract Background In a phase III clinical trial, CheckMate 025, treatment of metastatic renal cell carcinoma (mRCC) with nivolumab demonstrated superior efficacy over everolimus. However, as the clinical trial excluded patients with specific complications and poor performance status (PS), the effectiveness and safety of nivolumab in clinical practice, in which patients with various clinical complications are treated, is unclear. This study explored real-world nivolumab treatment in Japanese mRCC patients. Methods This is an interim analysis of a multicenter, non-interventional, medical record review study (minimum follow-up: 9 months). All eligible Japanese mRCC patients who first received nivolumab between February and October 2017 were included; data cut-off was April 2019. We analyzed nivolumab treatment patterns, efficacy (including overall survival, progression-free survival, objective response rate, and duration of response) and safety (including immune-related adverse events). Results Of 208 evaluable patients, 31.7% received nivolumab as fourth- or later line of treatment. At data cut-off, 26.9% of patients were continuing nivolumab treatment. The major reason for discontinuation was disease progression ( n = 100, 65.8%). Median overall survival was not reached; the 12-month survival rate was 75.6%. Median progression-free survival was 7.1 months, the objective response rate was 22.6%, and median duration of response was 13.3 months. Patients who were excluded or limited in number in CheckMate 025, such as those with non-clear cell RCC or poor PS, also received benefits from nivolumab treatment. Immune-related adverse events occurred in 27.4% of patients (grade ≥ 3, 10.1%). Conclusion Nivolumab was effective and well-tolerated in real-world Japanese mRCC patients. Trial registration UMIN000033312" @default.
• W3033436222 created "2020-06-12" @default.
• W3033436222 creator A5004714456 @default.
• W3033436222 creator A5004770487 @default.
• W3033436222 creator A5007365656 @default.
• W3033436222 creator A5013033064 @default.
• W3033436222 creator A5019215076 @default.
• W3033436222 creator A5023145056 @default.
• W3033436222 creator A5023422160 @default.
• W3033436222 creator A5032460607 @default.
• W3033436222 creator A5033437812 @default.
• W3033436222 creator A5041265628 @default.
• W3033436222 creator A5041954417 @default.
• W3033436222 creator A5057690027 @default.
• W3033436222 creator A5058934672 @default.
• W3033436222 creator A5059877323 @default.
• W3033436222 creator A5064971738 @default.
• W3033436222 creator A5065751906 @default.
• W3033436222 creator A5073146256 @default.
• W3033436222 creator A5079626310 @default.
• W3033436222 creator A5089017308 @default.
• W3033436222 creator A5090653734 @default.
• W3033436222 date "2020-06-09" @default.
• W3033436222 modified "2023-10-16" @default.
• W3033436222 title "A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data" @default.
• W3033436222 cites W2002108431 @default.
• W3033436222 cites W2043636495 @default.
• W3033436222 cites W2222086386 @default.
• W3033436222 cites W2259385916 @default.
• W3033436222 cites W2605642797 @default.
• W3033436222 cites W2605702182 @default.
• W3033436222 cites W2794864430 @default.
• W3033436222 cites W2891173803 @default.
• W3033436222 cites W2896622101 @default.
• W3033436222 cites W2896809746 @default.
• W3033436222 cites W2897013331 @default.
• W3033436222 cites W2897161734 @default.
• W3033436222 cites W2903486314 @default.
• W3033436222 cites W2915509794 @default.
• W3033436222 cites W2920962994 @default.
• W3033436222 cites W2928722477 @default.
• W3033436222 cites W2942674623 @default.
• W3033436222 cites W2943049136 @default.
• W3033436222 doi "https://doi.org/10.1007/s10147-020-01692-z" @default.
• W3033436222 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7392942" @default.
• W3033436222 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32519026" @default.
• W3033436222 hasPublicationYear "2020" @default.
• W3033436222 type Work @default.
• W3033436222 sameAs 3033436222 @default.
• W3033436222 citedByCount "19" @default.
• W3033436222 countsByYear W30334362222021 @default.
• W3033436222 countsByYear W30334362222022 @default.
• W3033436222 countsByYear W30334362222023 @default.
• W3033436222 crossrefType "journal-article" @default.
• W3033436222 hasAuthorship W3033436222A5004714456 @default.
• W3033436222 hasAuthorship W3033436222A5004770487 @default.
• W3033436222 hasAuthorship W3033436222A5007365656 @default.
• W3033436222 hasAuthorship W3033436222A5013033064 @default.
• W3033436222 hasAuthorship W3033436222A5019215076 @default.
• W3033436222 hasAuthorship W3033436222A5023145056 @default.
• W3033436222 hasAuthorship W3033436222A5023422160 @default.
• W3033436222 hasAuthorship W3033436222A5032460607 @default.
• W3033436222 hasAuthorship W3033436222A5033437812 @default.
• W3033436222 hasAuthorship W3033436222A5041265628 @default.
• W3033436222 hasAuthorship W3033436222A5041954417 @default.
• W3033436222 hasAuthorship W3033436222A5057690027 @default.
• W3033436222 hasAuthorship W3033436222A5058934672 @default.
• W3033436222 hasAuthorship W3033436222A5059877323 @default.
• W3033436222 hasAuthorship W3033436222A5064971738 @default.
• W3033436222 hasAuthorship W3033436222A5065751906 @default.
• W3033436222 hasAuthorship W3033436222A5073146256 @default.
• W3033436222 hasAuthorship W3033436222A5079626310 @default.
• W3033436222 hasAuthorship W3033436222A5089017308 @default.
• W3033436222 hasAuthorship W3033436222A5090653734 @default.
• W3033436222 hasBestOaLocation W30334362221 @default.
• W3033436222 hasConcept C121608353 @default.
• W3033436222 hasConcept C126322002 @default.
• W3033436222 hasConcept C141071460 @default.
• W3033436222 hasConcept C143998085 @default.
• W3033436222 hasConcept C197934379 @default.
• W3033436222 hasConcept C2777472916 @default.
• W3033436222 hasConcept C2777701055 @default.
• W3033436222 hasConcept C2778715236 @default.
• W3033436222 hasConcept C2780030458 @default.
• W3033436222 hasConcept C2780140570 @default.
• W3033436222 hasConcept C535046627 @default.
• W3033436222 hasConcept C61943457 @default.
• W3033436222 hasConcept C71924100 @default.
• W3033436222 hasConceptScore W3033436222C121608353 @default.
• W3033436222 hasConceptScore W3033436222C126322002 @default.
• W3033436222 hasConceptScore W3033436222C141071460 @default.
• W3033436222 hasConceptScore W3033436222C143998085 @default.
• W3033436222 hasConceptScore W3033436222C197934379 @default.
• W3033436222 hasConceptScore W3033436222C2777472916 @default.
• W3033436222 hasConceptScore W3033436222C2777701055 @default.
• W3033436222 hasConceptScore W3033436222C2778715236 @default.
• W3033436222 hasConceptScore W3033436222C2780030458 @default.
• W3033436222 hasConceptScore W3033436222C2780140570 @default.

• next